Taking control of fibrotic diseases through targeted therapeutics
Certa Therapeutics is a clinical stage biotechnology company developing innovative precision therapies for the treatment of fibrotic diseases.
Having identified and validated the role of GPR68, a G protein-coupled receptor (GPCR) receptor, as a switch regulating fibrosis, the company has built a platform to discover candidate drugs as potential treatments for multiple fibrotic diseases including serious and chronic conditions impacting the kidney, lung, skin, and heart.
Treatment of fibrosis is an unmet clinical need
Certa’s lead programme, FT011 (asengeprast), is being developed as a novel, first-in-class oral therapy for the treatment of systemic sclerosis (scleroderma) and has successfully completed a multi-national, phase II clinical trial. It has been awarded Orphan Drug Designation by the FDA and EMA for the treatment of scleroderma.
Further programs address major indications including chronic kidney disease, diabetic nephropathy and other chronic fibrotic indications.
A private company based in Melbourne Australia, Certa is backed by venture investors Brandon Capital and Uniseed
